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Abstract
Objectives
We assess the epidemiology and risk factors for mortality of bloodstream infection (BSI) in
patients with acute leukemia (AL).
Methods
Prospectively collected data of a cohort study from July 2004 to February 2016. Multivariate
analyses were performed.
Results
589 episodes of BSI were documented in 357 AL patients, 55% caused by gram-positive
bacteria (coagulase-negative staphylococci 35.7%, Enterococcus spp 10.8%) and 43.5%
by gram-negative bacteria (E. coli 21%, PA 12%). We identified 110 (18.7%) multidrug-
resistant (MDR) microorganisms, especially MDR-Pseudomonas aeruginosa (7%) and
extended-spectrum beta-lactamase producing Enterobacteriaceae (7%). The 30-day mor-
tality was 14.8%. Age (OR 3.1; 95% CI 1.7–5.7); chronic lung disease (4.8; 1.1–21.8); fatal
prognosis according to McCabe index (13.9; 6.4–30.3); shock (3.8; 1.9–7.7); pulmonary
infection (3.6; 1.3–9.9); and MDR-PA infections with inappropriate treatment (12.8; 4.1–
40.5) were related to mortality. MDR-PA BSI was associated to prior antipseudomonal ceph-
alosporin use (9.31; 4.38–19.79); current use of betalactams (2.01; 1.01–4.3); shock (2.63;
1.03–6.7) and pulmonary source of infection (9.6; 3.4–27.21).
Conclusions
MDR organisms were commonly isolated in BSI in AL. Inappropriate empiric antibiotic treat-
ment for MDR-PA is the primary factor related to mortality that can be changed. New
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treatment strategies to improve the coverage of MDR-PA BSI should be considered in those
patients with risk factors for this infection.
Introduction
Bloodstream infections (BSI) are frequently observed in patients with haematological malig-
nancies with a prevalence that ranges from 11% to 38% [1–5]. Crude mortality rates vary from
12% to 42%, and attributable mortality rates as high as 30% have been reported in some studies
[4–6]. Among patients with haematological malignancies, patients with acute leukemia (AL)
are a unique cohort. From AL diagnosis, patients undergo in a process with continuous cycles
of chemotherapy and profound prolonged neutropenia. Moreover, integrity alteration of the
gastrointestinal mucosa, and widespread use of indwelling intravascular catheters cause that
these patients are a high-risk group for BSI [1,3–5]. High consumption of antibiotics and pro-
longed hospitalizations might render these patients vulnerable to being colonized by multi-
drug-resistant (MDR) strains. Epidemiology of BSI in this population is in a continuous shift
due to changes in chemotherapies, immunosuppressive agents, and prophylaxis strategies.
However, in this era of problematic infections caused by MDR-bacteria, limited data have
been previously reported on epidemiology, outcomes and risk factors for mortality of BSI in
this specific patient group. This information is crucial for improving the empirical treatment
of patients and the potential antibiotic prophylaxis strategies. The knowledge of this epidemi-
ology should also be taken into account in the management of febrile neutropenia in AL
patients.
We aimed to describe the current epidemiology and its changes during the different cycles
of chemotherapy of BSI in a large current cohort of patients with AL. We also assessed the risk
factors for BSI mortality and the risk factors for BSI caused by MDR-Pseudomonas aeruginosa
(MDR-PA).
Materials and methods
Setting and data collection
This study was performed at the Hospital Clinic in Barcelona (Spain), a 700-bed university
center that provides specialized and broad medical, surgical, and intensive care for an urban
population of 500,000 people.
Since 1991 our institution has carried out a blood culture surveillance program identifying
and monitoring all patients with bacteraemia. The collected data were entered in a specific
database designed for this program. Patients were prospectively followed up 30 days after
onset, by a senior infectious disease specialist: patient’s medical history, physical examination,
the results of other microbiological tests and complementary imaging explorations were
assessed in order to determine the source of infection and recommend appropriate antibiotic
treatment.
Study population and design
For this study, we analysed all consecutive episodes of BSI occurring in patients with AL from
July 2004 to February 2016.
The following data were obtained from all patients: age, gender, comorbidities, McCabe
classification of underlying diseases, treatment with antibiotics or steroids in the previous
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month, recent hospitalization (within the last month), surgery and other invasive procedures,
presence of central venous catheter or urinary catheter, radiological findings, current adminis-
tration of anti-neoplastic chemotherapy, leucocyte count, source of bacteraemia, length of hos-
pitalization before diagnosis of BSI, days of neutropenia before BSI, mucositis, fever and shock
on presentation, intensive care unit and need for mechanical ventilation, etiologic microor-
ganisms and their susceptibility profile, empirical antibiotic treatment, appropriateness of
empirical therapy, definitive antibiotic therapy, and early and overall mortality.
The study was approved by the Ethics Committee board (Comité Ético de Investigación
Clı́nica del Hospital Clı́nic de Barcelona) of our institution.
Definitions
Neutropenia was defined as an absolute neutrophil count of<500 cells/mm3. Mucositis was
defined following the WHO criteria [7]. Prognosis of the underlying disease was classified,
according to McCabe and Jackson modified criteria, as rapidly fatal (death expected within 3
months), ultimately fatal (death expected within a period of>3 months but<5 years) and
non-fatal (life expectancy >5 years). Shock was defined as having a systolic pressure <90
mmHg that was unresponsive to fluid treatment or required vasoactive drug therapy. Prior
antibiotic therapy was defined as the use of any antimicrobial agent for3 days during the
month prior to the occurrence of the bacteraemic episode. According to the protocols of our
hospital, patients with an expected neutropenia over 10 days received prophylaxis with a fluo-
roquinolone. Definitions of healthcare-associated and community-acquired BSI as well as defi-
nition of the source of infection have been previously provided [8].
The following gram-negative bacilli were considered to be MDR: 1) extended-spectrum
beta-lactamase (ESBL) producing Enterobacteriaceae, 2) AmpC cephalosporinase hyperprodu-
cing Enterobacteriaceae, 3) MDR strains of non-fermenting GNB such as Pseudomonas aerugi-
nosa, Acinetobacter baumannii and Stenotrophomonas maltophilia. Non-fermenting GNB were
defined as MDR strains when they were resistant to at least 3 classes of antibiotics: carbape-
nems, ureidopenicillins, cephalosporins (ceftazidime and cefepime), monobactams, aminogly-
cosides, and fluoroquinolones. Extensively drug-resistant (XDR) GNB were those non-
susceptible to1 agent in all but2 categories. MDR gram-positive organisms included
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus
faecium (VRE).
Appropriate empirical therapy was considered when the patient received at least one in
vitro active antimicrobial agent within 24 h after obtaining blood cultures before susceptibility
results were available, and the dosage and route of administration were in accordance with
current medical standards. Early mortality was defined as death within 48 h of the onset of BSI
and overall mortality as death by any cause within the first 30 days of onset. Death was consid-
ered related to the BSI if it occurred before the resolution of symptoms or signs, or within 7
days of the onset of bacteraemia, and there was no other explanation.
Microbiological methods
Blood samples were processed using the BACTEC 9240 system or Bactec FX system (Becton-
Dickinson Microbiology Systems), with an incubation period of 5 days. Isolates were identified
by standard techniques. Antimicrobial susceptibility testing was performed by using a micro-
dilution system (Microscan WalkAway Dade Behring, West Sacramento, CA or Phoenix
system, Becton Dickinson, Franklin Lakes, NJ) or the Etest (AB Biodisk, Solna, Sweden/ bio-
Mérieux, Mercy l’Etoile, France). Current Clinical and Laboratory Standards Institute (CLSI)
or EUCAST breakpoints for each year were used to define susceptibility or resistance to these
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antimicrobial agents, and intermediate susceptibility was considered as resistance. All MDR
strains were confirmed by e-test methods over the study period.
Statistical analysis
Categorical variables were compared by Chi-square or Fisher’s exact test when necessary and
Student’s t-test or the Mann–Whitney U-test for continuous variables. Chi-square for trend
analysis was conducted to compare changes in epidemiology over time. Two multivariate
regression models (step-forward procedure) were used to identify the independent risk factors
for MDR-PA and the independent risk factors for overall mortality, respectively. The goodness
of fit of the multivariate models was assessed by the Hosmer-Lemeshow test and the area
under the receiver operating characteristic curve. The threshold for statistical significance was
defined as a two-tailed p<0.05. All analyses were done by using the SPSS software (version
18.0; SPSS, Inc., Chicago, IL).
Results
Demographics and epidemiology
In total, 589 BSI episodes of bloodstream infection in 357 patients with AL were documented
within the study period. Table 1 summarizes the demographic and clinical characteristics of
the patients. Most of the BSIs were nosocomially (52.6%) acquired. Three hundred and sixty-
two (61.5%) patients had received previous antibiotic therapy, mainly quinolones (34.5%),
cephalosporins (34.3%), and carbapenems (22.6%).
Table 2 details organisms responsible for all episodes of BSI. Gram-positive organisms
accounted for 55% of cases. The most frequent gram-positive isolated were coagulase-negative
staphylococci (35.7%), followed by Enterococcus spp (10.8%). Among gram-negative organ-
isms (43.5%), Escherichia coli (20.5%) was the most frequently isolated, followed by Pseudomo-
nas aeruginosa (12%). There were 25 (4%) episodes of candidemia. Forty-eight BSI episodes
were polymicrobial (8%). Patients with oral mucositis had more commonly candidemia
(10.9% vs 2.9%; p<0.001) and less commonly gram-negative bacteremia (34.7% vs 45.1%;
p = 0.055). No significant differences were found in gram-positive bacteremia (55.4% vs
54.9%; p = 0.924).
We identified 110 (18.7%) MDR organisms, mostly MDR-PA (6.9%) and ESBL-producing
E. coli and Klebsiella spp (6.9%). No vancomycin-resistant Enterococcus spp or carbapenemase-
producing Enterobacteriaceae were found. We did not identify any special temporal trend in
resistance or in causative BSI microorganisms during different chemotherapy cycles (Table 2).
Table 3 details epidemiological changes over time during the study period. No differences in
MDR-GNB or MDR-PA were found.
Therapeutic approaches and outcomes
Most patients received empirical antibiotics (96.8%), the most prevalent were carbapenems
(57%), glycopeptides (50.6%) and aminoglycosides (25.6%). Inadequate empirical antibiotic
therapy was given to 26.3% of patients. Table 4 summarizes the etiology of BSI in patients who
received inadequate empirical antibiotic treatment. Those patients with BSI due to a MDR
strain had a higher percentage of initial inadequate treatment than patients without MDR
strains (35.5% vs 24.4% p = 0.018).
Shock was documented in 11.2% of cases. Early mortality, overall mortality, and related
mortality within the first 30 days were 3.7%, 14.8% and 8.7%, respectively. In episodes caused
by MDR organisms the rates were 4.5%, 19.1% and 12.7%. In comparison to patients without
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MDR organisms, those with MDR organisms who received inappropriate antibiotic treatment
had higher early mortality (10.3%, p = 0.05), overall mortality (33.3%; p = 0.005) and related
mortality (20.5; p = 0.069), especially those with MDR-PA infection (early (15.8%, p = 0.03),
30-days (63.2%, p< 0.001) and related (36.8%, p< 0.001) mortality).
Predictors of mortality
Table 5 detailed the univariate analysis for mortality. Table 6 showed the multivariate analysis
of predictors for overall mortality. Age (OR 3.1; 95% CI 1.7–5.7); chronic lung disease (4.8;
1.1–21.8); fatal prognosis according to McCabe index (13.9; 6.4–30.3); shock at onset (3.8; 1.9–
7.7); pulmonary source of infection (3.6; 1.3–9.9); and BSI caused by MDR-PA with inappro-
priate antibiotic therapy (12.8; 4.1–40.5) were independent risk factors for overall mortality.
The goodness of fit of the multivariate model was assessed by the Hosmer-Lemeshow test
(0.784), and the discriminatory power of the score, as evaluated by the area under the receiver
operating characteristic curve, was 0.848 (95% 0.797–0.900), demonstrating a strong ability to
predict overall mortality in patients with AL and BSI.
Table 1. Demographic and clinical characteristics of 589 BSI episodes in patients with acute leukemia.
Episodes
N = 589 (%)
Demographics
Male sex 324 (55)
Age, median (IQR) years 53 (40.5–64)
Comorbid conditions
Diabetes mellitus 37 (6.3)
COPD 12 (2)
Clinical conditions
Previous hospital admission (last month) 254 (43)
Previous antibiotic therapy (last month) 362 (61.5)
Central intravenous vascular catheter 479 (81.3)
Urinary catheter 40 (6.8)
Corticosteroid therapy 204 (34.5)
Neutropenia (<500 neutrophils) 374 (63.5)







Unknown origin 294 (49.9)
Catheter-related 211 (35.8)
Pneumonia 27 (4.6)
Urinary tract 17 (2.9)
Abdominal 14 (2.4)
Skin and soft tissue infection 12 (2)
Cholangitis 1 (0.2)
IQR: Interquartile range.
COPD: Chronic Obstructive Pulmonary Disease.
https://doi.org/10.1371/journal.pone.0199531.t001
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Table 2. Detected microorganisms during different chemotherapy cycles.
Total
N = 589 (%)
Induction
N = 103 (%)
Consolidation
N = 176 (%)
Neutropenia
N = 376
Gram negative-bacteria 257 (43.6) 39 (37.9) 75 (42.6) 82 (39)
E. coli 120 (20.4) 13 (12.6) 40 (22.7) 95 (25.3)
Ciprofloxacin R 99 (82.5) 11 (84.6) 37 (92.5) 81 (85.3)
ESBL 31 (25.8) 2 (15.4) 9 (5.1) 24 (25.2)
Klebsiella spp 28 (4.8) 5 (4.9) 7 (4) 15 (4)
Ciprofloxacin R 13 (46.4) 4 (80) 5 (71.4) 9 (60)
ESBL 10 (35.7) 4 (80) 4 (2.3) 7 (46.6)
P. aeruginosa 71 (12) 12 (11.7) 23 (13.1) 43 (11.4)
Ciprofloxacin R 42 (59.2) 8 (66.7) 15 (65.2) 26 (60.5)
MDR 41 (57.7) 8 (66.7) 15 (65.2) 25 (58.1)
S. maltophilia 12 (2.0) 6 (5.8) 1 (0.6) 9 (2.4)
Enterobacter spp 8 (1.4) 1 1 (0.6) 4 (1.1)
Gram positive-bacteria 323 (55) 54 (52.4) 102 (58.0) 127 (60.5)
S. aureus 19 (3.2) 3 (2.9) 6 (3.4) 7 (1.9)
MRSA 4 (21) 0 0 1(0.3)
CoNS 211 (35.8) 34 (33) 76 (43.2) 135(35.9)
Enterococcus spp 64 (10.8) 12 (11.7) 9 (5.1) 37(9.8)
E. faecalis 29 (45.3) 2 (16.7) 5 (55.6) 11 (29.7)
E. faecium 33 (51.6) 10 (83.3) 4 (44.4) 21 (56.8)
VRE 0 0 0 0
S. pneumoniae 6 (1) 0 1 (0.6) 0
Group viridans streptococci 18 (3) 5 (4.9) 7 (4) 11(2.9)
L. monocytogenes 6 (1) 1 (1) 1 (0.6) 2(0.5)
Candida 25 (4.2) 13 (12.6) 4 (2.3) 19(5.1)
Polymicrobial 57 (9.6) 8 (7.8) 13 (7.4) 27(7.2)
MDR isolates 110 (18.7) 21 (20.4) 31 (17.6) 73 (19.5)
Percentage among their species.
https://doi.org/10.1371/journal.pone.0199531.t002
Table 3. Changes over time in epidemiology of BSI in HSCT recipients.
2004–2007
N = 233 (%)
2008–2011
N = 215 (%)
2012–2016
N = 141 (%)
p-value for trend
Gram-positive bacteria 137 (58.8) 113 (52.6) 73 (51.8) 0.151
CoNS 97 (41.6) 74 (34.4) 40 (28.4) 0.008
S. aureus 10 (4.3) 6 (2.8) 3 (2.1) 0.229
MRSA 2 (0.9) 2 (0.9) 0 0.378
Enterococcus spp 16 (6.9) 25 (11.6) 23 (16.3) 0.004
Gram-negative bacteria 92 (39.5) 103 (47.9) 60 (42.6) 0.405
E. coli 54 (23.2) 39 (18.1) 27 (19.1) 0.280
ESBL 15 (6.4) 8 (3.7) 8 (5.7) 0.611
P. aeruginosa 19 (8.2) 35 (16.3) 17 (12.1) 0.141
MDR 10 (4.3) 20 (9.3) 11 (7.8) 0.125
Klebsiella spp 8 (3.4) 13 (6) 7 (5) 0.404
ESBL 6 (2.6) 3 (1.4) 1 (0.7) 0.161
MDR isolates 43 (18.5) 44 (20.5) 23 (16.3) 0.703
Candidemia 10 (4.3) 3 (1.4) 12 (8.5) 0.123
https://doi.org/10.1371/journal.pone.0199531.t003
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Risk factors for BSI caused by MDR-PA
Independent factors associated with the isolation of MDR-PA in BSI in our cohort of patients
with AL were prior antipseudomonal cephalosporin use (OR 9.31; 95% CI 4.38–19.79); blood-
stream infection occurring within betalactam antibiotic therapy (2.01; 1.01–4.3); shock at
onset (2.63; 1.03–6.7) and pulmonary source of infection (9.6; 3.4–27.21). The goodness of fit
of the multivariate model was assessed by the Hosmer-Lemeshow test (0.658), and the discrim-
inatory power of the score, as evaluated by the area under the receiver operating characteristic
curve, was 0.807 (95% 0.724–0.890), demonstrating a strong ability to predict MDR-PA BSI.
Discussion
This prospective study describes the epidemiology and prognostic factors of a current cohort
of patients with AL presenting with a BSI. The most important findings were: 1) the propor-
tion of gram-positive and gram-negative bacteria isolated was similar 2) the causative microor-
ganisms did not change significantly between the different chemotherapy cycles 3) the
presence of MDR microorganisms, mainly GNB, was common 4) inadequate empirical antibi-
otic treatment was frequent, especially in patients with MDR BSI 5) the overall mortality was
high 6) independent risk factors for mortality were older age, chronic lung disease, fatal prog-
nosis according to McCabe index, shock at onset, pulmonary source of infection and BSI
caused by MDR-PA with inappropriate antibiotic therapy 7) independent risk factors for
MDR-PA BSI were prior antipseudomonal cephalosporin use, current use of betalactams,
shock at onset, and pulmonary source of infection.
The epidemiology of BSI in patients with AL is in a continuous shift [4,5,9,10]. Our current
data showed a slight predominance of Gram-positive organisms, mainly CoNS and entero-
cocci. Moreover, we documented an important number of patients with BSI caused by Gram-
negative bacilli. These results are similar to those obtained in comparable centers in overall
haematological patients [11–14].
The development of multidrug resistance has become a major health problem worldwide
[15–16]. Information dealing with the current epidemiology and outcomes of MDR-bacteria
in patients with haematological malignancies is scarce [6,17,18], and there specifically lacks
data in the AL population. We found a high proportion of MDR isolates, predominantly
Table 4. Most frequent microbiological isolates in those 155 BSI episodes who received inappropriate antibiotic
therapy.
Microorganism Inadequate initial empirical therapy
N = 155 (%)
Gram negative-bacteria




S. maltophilia 9 (5.8)
Gram positive-bacteria
CoNS 65 (41.9)
Enterococcus spp 22 (14.2)
E. faecium 14 (63.6)
Candida spp 16 (10.3)
Percentage pertaining to their species.
https://doi.org/10.1371/journal.pone.0199531.t004
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MDR-PA and ESBL producing E. coli and K. pneumoniae. Among Gram-positive organisms,
resistance to methicillin in S. aureus isolates was relatively low (0.7%) in this population, and
as expected in our geographical area no vancomycin-resistant Enterococcus were detected
[19,20]. Our study confirms that a high number of patients with MDR-BSI receive an inappro-
priate empirical treatment. Remarkably, we did not find differences in global microbiology
Table 5. Univariate analysis for mortality.
Deaths
N = 87 (%)
Survivors
N = 502 (%)
p value
Clinical characteristics
Male sex 45 (51.7) 279 (55.7) 0.493
Older age (>65 years old) 47 (54) 95 (18.9) < 0.001
Diabetes mellitus 11 (12.6) 26 (5.2) 0.008
Chronic lung disease 5 (5.7) 7 (1.4) 0.008
Chronic liver disease 2 (2.3) 4 (0.8) 0.218
Corticosteroid therapy 36 (41.4) 167 (33.3) 0.151
Neutropenia (<500 neutrophils) 47 (54) 327 (65.1) 0.069
Prolonged neutropenia (more than 21 days) 18 (20.7) 55 (11) 0.011
Mucositis 6 (6.9) 95 (18.9) 0.006
BSI in the first month after AL diagnosis 19 (21.8) 80 (15.9) 0.177
AL in induction treatment 15 (17.2) 88 (17.5) 0.948
Fatal prognosis according to McCabe index 29 (33.3) 16 (3.2) < 0.001
Site of acquisition
Nosocomial 43 (49.4) 267 (53.2) 0.547
Community 9 (10.3) 19 (3.8) 0.008
Source of bacteraemia
Unknown origin 38 (43.7) 256 (51) 0.208
Catheter-related 22 (25.3) 189 (37.6) 0.026
Pulmonary source of infection 13 (14.9) 14 (2.8) < 0.001
Urinary tract 5 (5.7) 12 (2.4) 0.084
Intraabdominal source of infection 5 (5.7) 9 (1.8) 0.025
Etiology
S. aureus 2 (2.3) 17 (3.4) 0.596
CoNS 12 (13.8) 119 (23.7) < 0.001
Group viridans streptococci 0 (0) 18 (3.6) 0.091
Enterococcus spp 15 (17.2) 49 (9.8) 0.038
E. coli 17 (19.5) 103 (20.5) 0.834
P. aeruginosa 24 (27.6) 47 (9.4) < 0.001
Klebsiella spp 7 (8) 21 (4.2) 0.118
Candida spp 5 (5.7) 20 (4) 0.451
Polymicrobial 9 (10.3) 39 (7.8) 0.418
MDR strain 21 (24.1) 89 (17.7) 0.157
Inappropriate antibiotic therapy
Clinical and treatment features
Shock at onset 23 (26.4) 43 (8.6) < 0.001
Persistent bacteremia 12 (13.8) 85 (16.9) 0.486
Inappropriate antibiotic therapy 30 (34.5) 125 (24.9) 0.055
Inappropriate antibiotic therapy in MDR strains 13 (14.9) 26 (5.2) 0.001
Inappropriate antibiotic therapy in MDR-PA 12 (13.8) 7 (1.4) < 0.001
https://doi.org/10.1371/journal.pone.0199531.t005
Bloodstream infections in patients with acute leukemia
PLOS ONE | https://doi.org/10.1371/journal.pone.0199531 June 28, 2018 8 / 12
and MDR isolates according to the different chemotherapy phases. The finding that antibiotic
resistance did not change during the progressive cycles of therapy might be explained by the
fact that initial induction chemotherapy is the most aggressive cycle of chemotherapy; always
administered at hospital; with the host in the weakest state, and with a high antibiotic pressure.
In the present study, we found early and overall mortality rates of 3.7% and 14.8% respec-
tively, with a related mortality of 8.7%. These findings are consistent with other studies involv-
ing patients with haematological malignancies [4–6,12,21]. We identify some factors related
with overall mortality (older age, chronic lung disease, fatal prognosis according to McCabe
index, shock at onset, pulmonary source of infection) that concords with previous research
conducted mainly in patients with overall haematological malignances [22–25]. Also, we iden-
tify that inadequate empirical therapy for MDR-PA BSI was associated with an 11-fold increase
in mortality. This factor is important because it can be modified.
The incidence of MDR-PA has recently increased worldwide [26,27]. The impact of inap-
propriate empirical antibiotic therapy in mortality of BSI caused by MDR-PA has been a mat-
ter of debate for many years with conflicting results [28–30]. The discrepancies among studies
reflect the complexity of this infection and the key role that antibiotic therapy not only plays,
but as well as host factors, source of infection or removal of infection site. However, to our best
knowledge, specific studies on the impact of inappropriate antibiotic therapy in BSI caused by
MDR-PA in AL population have not been previously reported.
Improving the recognition of patients with AL and BSI at risk of MDR-PA is mandatory.
We identified that those patients with prior antipseudomonal cephalosporin use, those who
had current use of betalactamics, and those with shock at onset or/and pulmonary source of
infection had a high risk for BSI caused by MDR-PA. Surveillance data of the resistance mech-
anisms of PA in the geographical area or institution may help to choose the best optimal anti-
biotic regimen. Whether the screening of MDR-strains colonization might help to diminish
inappropriate empirical antibiotic therapy remains a matter of debate [31,32]. Initial approach
of these patients with an empirical antibiotic therapy comprising of a combination of a carba-
penem in continuous infusion, with either an aminoglycoside or a different antipseudomonal
approach including ceftolozane/tazobactam, might be suitable options.
The strengths of this study are the large number of patients included, the prospective collec-
tion of the data, and the comprehensive clinical and microbiologic data gathered. However,
there are some limitations that should be acknowledged. Our study was conducted at a single
center; considering that different microbiological epidemiology varies widely from hospital to
hospital and even in different wards of the same hospital, it is difficult to generalize some con-
clusions drawn. Furthermore, we perform quinolone prophylaxis for patients expecting to
Table 6. Independent risk factors for mortality.
Risk factor Adjusted odds ratio (95% CI) p-value
Older age (>65 years old) 3.116 (1.698–5.719) <0.001
Chronic lung disease 4.890 (1.096–21.818) 0.033
Fatal prognosis according to McCabe index 13.89 (6.373–30.291) <0.001
Pulmonary source of infection 3.582 (1.296–9.903) 0.014
Shock at onset 3.789 (1.865–7.698) <0.001
BSI caused by MDR-PA with inappropriate antibiotic therapy 12.818 (4.056–40.502) <0.001
Adjusted for: mucositis, diabetes, communitary-infection, intrabdominal source of infection, catheter source of
infection, prolonged neutropenia (more than 21 days), BSI caused by Enteroccocus spp, inappropriate antibiotic
treatment, and BSI caused by MDR-bacteria with inappropriate antibiotic therapy.
https://doi.org/10.1371/journal.pone.0199531.t006
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have a neutropenia longer than 10 days, making our results perhaps different from those other
centers who do not perform prophylaxis.
In conclusion, we found a similar proportion of Gram-positive and Gram-negative organ-
isms producing BSI in patients with AL, without changes according to the chemotherapy
phase. MDR microorganisms were frequent and commonly received inadequate empirical
antibiotic therapy. Mortality in patients with AL and BSI remains high, especially in older
patients with poor baseline prognosis, and in patients with severe infection at onset. Improving
empirical antibiotic treatment, especially for patients with BSI caused by MDR-PA, is needed.
There must be a high suspicion of infection caused by MDR-PA in patients presenting with
prior antipseudomonal cephalosporin use, current use of betalactamics at BSI onset, shock, or
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for Research and Innovation in HealthCare’)]. The funder had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Author Contributions
Conceptualization: Alex Soriano.
Investigation: Carolina Garcia-Vidal, Jose Antonio Martinez, Alex Soriano.
Methodology: Francesc Marco, Josep Mensa, Alex Soriano.
Writing – original draft: Carolina Garcia-Vidal, Celia Cardozo-Espinola, Pedro Puerta-
Alcalde, Francesc Marco, Adrian Tellez, Daiana Agüero, Francisco Romero-Santana,
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